ASCENT-05: Adjuvant Sacituzumab Govitecan Plus Pembrolizumab for Patients with Triple Negative Breast Cancer
Condition: Breast Cancer
Sponsor: Gilead Sciences, Inc.
Protocol GS-US-595-6184: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Arm A: Anti-TROP2 antibody-drug conjugate sacituzumab govitecan + pembrolizumab
Arm B: pembrolizumab +/- capecitabine
Non-metastatic triple negative breast cancer treated with neoadjuvant systemic therapy followed by surgery.
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.